Boston is the world's leading life sciences M&A hub, with $14.8 billion in biotech deals across 320+ companies in 2025 - more than San Francisco and San Diego combined. This list covers 14 active life sciences M&A advisors in 2026, with deal sizes, sector focus, and verified recent transactions.
Boston life sciences M&A in 2026
Boston's Kendall Square is the most active biotech M&A corridor in the world. In 2025, pharma sector M&A globally reached $228B+ in deal value. Boston alone closed $14.8B in biotech deals - more than any other US city outside New York by deal value.
The deal drivers in 2026 are patent cliff pressure, pipeline-building acquisitions, and AI-enabled drug discovery platforms commanding premium multiples. Strategic buyers from Sanofi, Novartis, and AstraZeneca all have active BD teams in Boston looking for mid-stage programs.
Set up an Ellty data room before your first advisor conversation. Life sciences buyers check IP ownership, clinical data packages, and partnership agreements before sending a term sheet.
Ellty's document access controls let you stage which buyers see your preclinical data vs. your full IP portfolio. Control access by NDA tier so sensitive pipeline data reaches only buyers who've signed confidentiality agreements.
What separates Boston life sciences advisors
Leerink Partners is now the No. 1 market share investment bank in biopharma stock deals, overtaking Jefferies and JPMorgan for the first time in 2025. They advised GSK on its acquisition of local Boston biotech IDRx and Tourmaline Bio on its sale to Novartis.
Aquilo Partners is the deepest life-sciences-only boutique in the market with $30B+ in completed transactions and Boston Managing Director John Dyer. Aquilo advised Adverum Biotechnologies on its sale to Eli Lilly in December 2025 and Curio Bioscience on its sale to Takara Bio in January 2025.
Life sciences M&A requires advisors who understand FDA regulatory timelines, IP licensing structures, and how clinical milestone timing affects buyer valuations. A general M&A advisor without biotech experience will miss valuation variables that can cost you 30-50% on deal price.
| Advisor | Deal Type | Deal Size | Sector Focus | Website | |
|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Both | $100M-$10B+ | Biopharma, oncology, rare disease, medical devices, health tech | leerink.com |
| Aquilo Partners | Aquilo Partners | Both | $50M-$500M+ | Biotech, biopharma, drug discovery platforms, life sciences tools | aquilopartners.com |
| Back Bay Life Science Advisors | Back Bay Life Science Advisors | Both | $10M-$500M | BioPharma, biotech, medtech, diagnostics, life science services | bblsa.com |
| Piper Sandler (Life Sciences) | Piper Sandler (Life Sciences) | Both | $50M-$2B+ | Biotech, pharma, medical devices, diagnostics, life sciences tools | pipersandler.com |
| Jefferies (Life Sciences) | Jefferies (Life Sciences) | Both | $100M-$10B+ | Biopharma, biotech, gene therapy, oncology, pharma services | jefferies.com |
| Goldman Sachs (Life Sciences) | Goldman Sachs (Life Sciences) | Both | $500M-$50B+ | Large-cap pharma, biotech, medtech, life sciences platforms | goldmansachs.com |
| J.P. Morgan (Life Sciences) | J.P. Morgan (Life Sciences) | Both | $500M-$50B+ | Pharma, biotech, medical devices, life sciences tools, diagnostics | jpmorgan.com |
| Guggenheim Securities (Healthcare) | Guggenheim Securities | Both | $100M-$5B+ | Biopharma, medical devices, diagnostics, tools, healthcare services | guggenheimsecurities.com |
| Houlihan Lokey (Life Sciences) | Houlihan Lokey (Life Sciences) | Both | $50M-$5B+ | Life sciences, pharma, medtech, health tech, biotech services | hl.com |
| William Blair (Life Sciences) | William Blair (Life Sciences) | Both | $50M-$2B+ | Life sciences, medtech, pharma outsourcing, health IT, diagnostics | williamblair.com |
| Barclays (Life Sciences) | Barclays (Life Sciences) | Both | $200M-$10B+ | Pharma, biotech, medtech, healthcare services, life sciences tools | barclays.com |
| Lincoln International (Life Sciences) | Lincoln International (Life Sciences) | Both | $50M-$1B+ | Life sciences, pharma outsourcing, medtech, health IT, diagnostics | lincolninternational.com |
| Raymond James (Life Sciences) | Raymond James (Life Sciences) | Both | $25M-$1B+ | Specialty pharma, medical devices, healthcare services, diagnostics | raymondjames.com |
| Harris Williams (Life Sciences) | Harris Williams (Life Sciences) | Both | $50M-$2B+ | Healthcare & life sciences, medical products, pharma services, diagnostics | harriswilliams.com |
How to verify a life sciences advisor's biotech deal record
Ask for a closed deal list with company names, deal sizes, and acquirer names from the last 24 months. A credible Boston life sciences advisor closes 10+ transactions per year with named pharma, medtech, or PE buyers.
Check whether the advisor has sold to both strategic buyers (large pharma) and financial buyers (PE, crossover funds). Selling to AstraZeneca is structurally different from selling to a PE platform. Advisors who've done both know what each buyer demands in diligence.
Ask specifically who will run your deal day-to-day. At large banks, the Managing Director pitching often delegates to a junior associate. Life sciences diligence requires senior-level engagement throughout - not just at the pitch.
Use Ellty to share your clinical data summary with buyers through tracked document links. You'll know which pharma BD teams access your preclinical package before deciding who to invite for full diligence.
Read the Boston M&A advisors guide for context on the full Boston advisory market before selecting a life sciences-specific firm.
Running a life sciences M&A process in Boston?
Organize your IP, clinical data, and partnership agreements before pharma buyers start diligence.
Start free 14-day trialWhat pharma buyers check first in Boston biotech diligence
Pharma corporate development teams run a consistent diligence playbook for Boston biotech acquisitions. IP ownership and freedom-to-operate (FTO) analysis is always the first check. Clinical data package quality follows immediately.
IP chain of title issues - unassigned inventor assignments, third-party licensing encumbrances, open-source software in AI platforms - are the most common cause of deal delays in Boston biotech. Fix these before going to market.
Clinical data reproducibility is the second check. Buyers who can't replicate your preclinical results will reprice at Phase 2 data readout terms rather than preclinical valuation. Make sure your data room includes all raw data files, lab notebooks, and statistical analysis code.
Partnership agreements with academic institutions (Harvard, MIT, Broad Institute) require careful novation analysis. Buyers need to understand what rights they're acquiring vs. what remains licensed to the institution.
Use Ellty to organize your IP files and clinical data packages before buyers start diligence. Life sciences buyers who find complete IP documentation in the data room move to term sheet without the repricing conversations.
| Diligence Area | What pharma buyers check | Common issues that reprice deals | |
|---|---|---|---|
| IP Ownership | IP Ownership | Patent assignments, inventor records, FTO analysis | Unassigned inventors, academic institution rights, open-source IP |
| Clinical Data | Clinical Data | Preclinical data packages, Phase 1/2 results, manufacturing data | Non-reproducible data, missing raw files, undocumented protocol changes |
| Regulatory | Regulatory Status | IND status, FDA correspondence, clinical hold history | Undisclosed clinical holds, FDA correspondence gaps |
| Partnerships | Partnerships & Licenses | Academic licenses, co-development agreements, CRO contracts | Restrictive academic licenses, change-of-control rights, sublicensing caps |
| Manufacturing | Manufacturing | CMO agreements, batch records, CMC documentation | Single-source CMO, missing batch records, process transfer risk |
14 Boston life sciences M&A advisors in 2026
These firms are active in biotech, biopharma, pharma, medtech, and life sciences tools M&A in Boston in 2026.
1. Leerink Partners
Leerink Partners is the No. 1 market share investment bank in biopharma stock deals, overtaking Jefferies and JPMorgan for the first time in 2025. Founded in 1995 by Jeffrey Leerink in Boston, the firm covers biopharma, oncology, rare disease, and medical devices with offices in Boston, New York, San Francisco, London, and five other cities. In 2025, Leerink advised GSK on its acquisition of IDRx (a Boston clinical-stage biotech focused on gastrointestinal cancers) and Tourmaline Bio on its sale to Novartis.
Recent Deals: Advised GSK on its acquisition of IDRx (Boston biotech, oncology, 2025). Advised Tourmaline Bio on its sale to Novartis (2025). Named No. 1 in biopharma stock deal market share for the first time in 2025.
LinkedIn: Leerink Partners on LinkedIn
Sector Focus: Biopharma, oncology, rare disease, medical devices, health tech
Deal Type: Both
Deal Size: $100M-$10B+
Location: Boston, MA (headquarters, 8 global offices)
Website: leerink.com
2. Aquilo Partners
Aquilo Partners is a life-sciences-only specialty boutique with $30B+ in completed M&A and capital transactions. Boston Managing Director John Dyer joined in 2009 from JPMorgan biotech investment banking. In January 2025, Aquilo advised Curio Bioscience on its sale to Takara Bio. In December 2025, Aquilo advised Adverum Biotechnologies on its sale to Eli Lilly for approximately $261.7 million.
Recent Deals: Advised Adverum Biotechnologies on its sale to Eli Lilly for approximately $261.7M (December 2025). Advised Curio Bioscience on its sale to Takara Bio (January 2025). $30B+ in total lifetime transactions.
LinkedIn: Aquilo Partners on LinkedIn
Sector Focus: Biotech, biopharma, drug discovery platforms, life sciences tools
Deal Type: Both
Deal Size: $50M-$500M+
Location: Boston, MA (office, SF and NYC offices)
Website: aquilopartners.com
3. Back Bay Life Science Advisors
Back Bay Life Science Advisors is a Boston-headquartered boutique providing M&A, licensing, due diligence, and investment banking advisory exclusively to biotech, pharma, and medical device companies. Their integrated advisory model with DNB Bank provides cross-border European strategic acquirer reach for $10M-$500M transactions. The firm has completed more than $23 billion in transactional experience.
Recent Deals: Active in biopharma, biotech, and medtech M&A advisory through 2025-2026 with $23B+ in total transactional experience and European buyer reach through DNB Bank.
LinkedIn: Back Bay Life Science Advisors on LinkedIn
Sector Focus: BioPharma, biotech, medtech, diagnostics, life science services
Deal Type: Both
Deal Size: $10M-$500M
Location: Boston, MA (headquarters)
Website: bblsa.com
4. Piper Sandler (Life Sciences)
Piper Sandler runs one of the most active biotech and life sciences M&A and capital markets practices in the US, with a research-backed approach that gives Boston biotech founders real-time buyer sentiment data. Their Boston team covers biotech, pharma, medical devices, and diagnostics with PE and strategic buyer relationships across the Northeast. Piper Sandler is particularly active in biotech capital markets and M&A across the Kendall Square corridor.
Recent Deals: Active in biotech, pharma, and medical device M&A advisory through 2025-2026 with dedicated Boston coverage and one of the most active biotech research departments in the market.
LinkedIn: Piper Sandler on LinkedIn
Sector Focus: Biotech, pharma, medical devices, diagnostics, life sciences tools
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (East Coast office, national network)
Website: pipersandler.com
Life sciences M&A data room in Boston
Share your IP and clinical data securely with pharma buyers and PE firms.
Start free 14-day trial5. Jefferies (Life Sciences)
Jefferies has one of the largest life sciences investment banking practices in the US, covering biopharma, biotech, gene therapy, and oncology across both M&A and capital markets. In 2025, Leerink overtook Jefferies for the No. 1 spot in biopharma stock deal market share - indicating the fierce competition and deal volume in Boston's life sciences M&A market. Jefferies provides global buyer access for Boston biotech founders targeting international pharma strategic acquirers.
Recent Deals: Active in biopharma, biotech, and gene therapy M&A advisory through 2025-2026 with global buyer access and top-ranked life sciences research coverage.
LinkedIn: Jefferies on LinkedIn
Sector Focus: Biopharma, biotech, gene therapy, oncology, pharma services
Deal Type: Both
Deal Size: $100M-$10B+
Location: Boston, MA (East Coast office, global network)
Website: jefferies.com
6. Goldman Sachs (Healthcare and Life Sciences)
Goldman Sachs covers large-cap pharma and biotech M&A from its Boston office, providing access to corporate development teams at the world's largest pharmaceutical buyers. Their involvement in billion-dollar-plus life sciences transactions - including advising Xpress Wellness (a Houlihan Lokey deal competitor in 2025) - reflects their position as a standard advisor at the upper end of the Boston life sciences M&A market.
Recent Deals: Active in large-cap pharma, biotech, and medtech M&A advisory through 2025-2026 at the $500M+ transaction tier with global buyer reach.
LinkedIn: Goldman Sachs on LinkedIn
Sector Focus: Large-cap pharma, biotech, medtech, life sciences platforms
Deal Type: Both
Deal Size: $500M-$50B+
Location: Boston, MA (office, global network)
Website: goldmansachs.com
7. J.P. Morgan (Life Sciences)
J.P. Morgan runs the JPMorgan Healthcare Conference each January, the most important deal-sourcing event in the life sciences industry. Their Boston office covers pharma, biotech, medical devices, and life sciences tools at the upper end of the transaction market. J.P. Morgan's buyer network reaches every major pharma corporate development team globally.
Recent Deals: Active in pharma, biotech, and medical device M&A advisory through 2025-2026 with global buyer access and the most recognized annual healthcare investor conference.
LinkedIn: J.P. Morgan on LinkedIn
Sector Focus: Pharma, biotech, medical devices, life sciences tools, diagnostics
Deal Type: Both
Deal Size: $500M-$50B+
Location: Boston, MA (office, global network)
Website: jpmorgan.com
8. Guggenheim Securities (Healthcare)
Guggenheim Securities provides independent M&A advisory across biopharma, medical devices, tools and diagnostics, and healthcare services. They advised Acelyrin on its merger with Alumis in 2025, demonstrating active biotech M&A advisory in the mid-market. Guggenheim's independence from commercial banking creates fewer conflict-of-interest concerns than full-service investment banks for biotech founders considering a sale.
Recent Deals: Advised Acelyrin on its merger with Alumis (2025). Active in biopharma, medical devices, and diagnostics M&A advisory through 2025-2026.
LinkedIn: Guggenheim Securities on LinkedIn
Sector Focus: Biopharma, medical devices, diagnostics, tools, healthcare services
Deal Type: Both
Deal Size: $100M-$5B+
Location: Boston, MA (East Coast coverage, national network)
Website: guggenheimsecurities.com
9. Houlihan Lokey (Life Sciences)
Houlihan Lokey's Healthcare Group achieved its most successful year in firm history in 2025, covering life sciences, pharma, medtech, and health tech. Their Boston life sciences team provides mid-market biotech and medtech founders access to a buyer network covering both PE acquirers and strategic pharma buyers. Houlihan Lokey is particularly active in life sciences capital advisory alongside M&A.
Recent Deals: Active in life sciences, pharma, medtech, and health tech M&A through 2025-2026. Healthcare group achieved record performance in 2025 across M&A and capital advisory mandates.
LinkedIn: Houlihan Lokey on LinkedIn
Sector Focus: Life sciences, pharma, medtech, health tech, biotech services
Deal Type: Both
Deal Size: $50M-$5B+
Location: Boston, MA (office, global network)
Website: hl.com
10. William Blair (Life Sciences)
William Blair covers life sciences, medtech, pharma outsourcing, and health IT, with a Boston team that bridges the life sciences and health technology sectors. William Blair advised Sartorius on its acquisition of MatTek (a BICO Group subsidiary) for US$63M in December 2025, demonstrating active advisory in life sciences tools and medtech adjacent sectors.
Recent Deals: Advised Sartorius on its $63M acquisition of MatTek from BICO Group (December 2025). Completed 17 healthcare technology M&A advisory deals in 2025. Active in life sciences, medtech, and pharma outsourcing M&A.
LinkedIn: William Blair on LinkedIn
Sector Focus: Life sciences, medtech, pharma outsourcing, health IT, diagnostics
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (office, national network)
Website: williamblair.com
11. Barclays (Life Sciences)
Barclays runs an active life sciences M&A and equity capital markets practice with dedicated biotech research coverage. Barclays published a detailed 2025 trends analysis for biotech and pharma M&A and IPOs, reflecting their sector depth. Their Boston team covers pharma, biotech, medtech, and healthcare services at mid-to-large cap transaction sizes.
Recent Deals: Active in pharma, biotech, medtech, and healthcare services M&A advisory through 2025-2026 with dedicated Boston coverage and published biotech and pharma M&A research.
LinkedIn: Barclays on LinkedIn
Sector Focus: Pharma, biotech, medtech, healthcare services, life sciences tools
Deal Type: Both
Deal Size: $200M-$10B+
Location: Boston, MA (East Coast office, global network)
Website: investmentbank.barclays.com
12. Lincoln International (Life Sciences)
Lincoln International completed more than 45 healthcare and life sciences transactions in an 18-month period through 2025. Their global network gives Boston life sciences founders cross-border buyer access to European and Asian strategic acquirers, including European pharma companies looking for US platform acquisitions. Lincoln's recent 8 Managing Director hires demonstrate active investment in life sciences deal capacity.
Recent Deals: Completed 45+ healthcare and life sciences transactions in the 18 months through 2025. Active in life sciences, pharma outsourcing, and medtech M&A through 2025-2026 with global buyer access.
LinkedIn: Lincoln International on LinkedIn
Sector Focus: Life sciences, pharma outsourcing, medtech, health IT, diagnostics
Deal Type: Both
Deal Size: $50M-$1B+
Location: Boston, MA (East Coast coverage, Chicago headquarters)
Website: lincolninternational.com
13. Raymond James (Life Sciences)
Raymond James covers specialty pharma, medical devices, and healthcare services with a research-backed advisory approach. Their Boston life sciences team serves founders at deal sizes from $25M to $1B, filling the mid-market gap between the specialist boutiques and the large banks. Raymond James is particularly active in specialty pharma and medical device M&A in the Northeast.
Recent Deals: Active in specialty pharma, medical devices, and healthcare services M&A through 2025-2026 with East Coast coverage and research-backed deal process.
LinkedIn: Raymond James on LinkedIn
Sector Focus: Specialty pharma, medical devices, healthcare services, diagnostics
Deal Type: Both
Deal Size: $25M-$1B+
Location: Boston, MA (East Coast office, national network)
Website: raymondjames.com
14. Harris Williams (Healthcare and Life Sciences)
Harris Williams runs quarterly life sciences market reports tracking deal activity across medical products and devices, healthcare technology, and value-based care - the most active sub-sectors for Boston-area life sciences M&A. Their PE firm relationships give Boston life sciences founders access to the full set of PE platforms actively running healthcare consolidations.
Recent Deals: Active in healthcare & life sciences, medical products, and pharma services M&A through 2025-2026 with quarterly sector market reports and dedicated East Coast coverage.
LinkedIn: Harris Williams on LinkedIn
Sector Focus: Healthcare & life sciences, medical products, pharma services, diagnostics, health IT
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (East Coast coverage, national network)
Website: harriswilliams.com
How academic institution IP affects Boston biotech M&A
Harvard, MIT, and the Broad Institute are the most common sources of licensed IP in Boston biotech companies. How that IP is structured affects deal value more than almost any other factor.
Academic licenses with field-of-use restrictions, change-of-control provisions, or sublicensing caps can significantly constrain a buyer's ability to realize the full value of an acquisition. Buyers reprice for restricted academic licenses.
Work with your advisor and IP counsel before starting a sale process to understand exactly what IP rights the academic institution retains. Negotiate favorable change-of-control terms before you start the process - not after you've already been acquired.
Use Ellty to share your IP licensing agreements securely with buyers during data room diligence. Academic IP documentation that's organized and easy to review reduces the risk of buyer confusion and unnecessary repricing.
What clinical milestone timing means for deal value
Boston biotech M&A valuations are milestone-driven. A company with Phase 2 data in hand gets a different valuation than the same company six months before that data is available.
The best time to run a Boston biotech M&A process depends on your clinical calendar. Your advisor should help you model the optimal timing around upcoming data readouts, IND filings, and FDA interactions.
Advisors who start a process before an important data readout create optionality - if the data is positive, you can accelerate the process. If the data is disappointing, you haven't wasted six months of process with negative momentum.
Read the startup fundraising guide to understand how biotech-specific financing rounds compare to M&A exit terms before deciding which path fits your company's situation.
How Ellty helps you run a Boston life sciences M&A process
Once you have your advisor, organize your IP and clinical data. Pharma buyers start diligence with IP ownership and data package review.
- 1.Upload IP records, clinical data, and partnership agreementsAdd patent assignments and regulatory documentation before buyer outreach.
- 2.Stage access by NDA tier and buyer typeControl who sees your full IP portfolio and clinical data packages.
- 3.Track which pharma buyers access your data roomSee which corporate development teams review your clinical data in real time.
Common questions about Boston life sciences M&A advisors
- Leerink Partners achieved the largest market share of any investment bank in biopharma stock deals in 2025, overtaking Jefferies and JPMorgan for the first time. They're headquartered in Boston and have expanded to 8 global offices.
- Aquilo Partners and Back Bay Life Science Advisors both focus exclusively on life sciences M&A. Aquilo has completed $30B+ in transactions with a Boston office led by John Dyer. Back Bay covers $10M-$500M with European acquirer reach.
- Expect five to nine months. Life sciences deals with FDA clinical holds, academic IP complications, or complex licensing structures often run nine to twelve months.
- Academic licenses from Harvard, MIT, or the Broad Institute with change-of-control restrictions or sublicensing caps significantly reduce buyer valuations. Negotiate favorable change-of-control terms before starting the sale process.
- Expect 2-4% for deals under $100M and 1-2% for deals above $500M. Life-sciences-only boutiques charge similar rates to large banks, with the difference being senior banker engagement throughout vs. junior associate handoffs at large banks.
- Time the process around your clinical calendar. Start 3-6 months before an important data readout to create optionality. Going to market after a failed data readout significantly reduces valuation and buyer interest.
